Chronic portfolio may help Cipla sustain growth outperformance in near term

Topics Cipla | Pharma stocks | Markets

Led by higher sales of Covid-related drugs, Cipla reported double-digit growth in domestic sales for the third consecutive month. The company posted sales growth of 13.5 per cent, as compared to 1.3 per cent for the Indian pharmaceutical market (IPM) sector. Adjusted for sales of Covid drugs, such as Remdesivir, growth is pegged at just under 4 per cent, which is still higher than the market growth. Average growth over the last three months has been 17.6 per cent, as compared to IPM’s 5.3 per cent.  While Covid-related sales may come down going ahead, analysts expect the.....

Key stories on are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel